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Introduction
N6-(Δ2-Isopentenyl)adenosine (1, IPA), is a modified nucleoside found in a subset of tRNAs of many eukaryotic and prokaryotic cells whose complete biological significance is so far unknown [1,2].
At the moment, IPA is the only known cytokinin existing in animal tRNAs and modulates the expression of the human tRNA-isopentenyltransferase (TRIT1). IPA is capable to inhibit the growth of human and mouse tumour cells in vitro [3] but the same activity is not observed in vivo [4,5]. A possible explanation for lack of in vivo activity could be related to cleavage of the β-N-glycosidic bond by purine catabolic enzymes, such as, for instance, nucleoside phosphorylase.  

Aim of the project/Experimental approach
The PhD project will investigate structural modifications of IPA with the aim of identifying compounds endowed with in vitro and in vivo antiproliferative activity. In this first year, we have substituted the N6-isopentenyl with the N6-isopentyl moiety (compound 2) that has been prepared by reaction of 6-chloropurine riboside and isopentylamine.
We have also synthesized acyclonucleosides 3-6, analogues of the antiviral drug penciclovir [6], characterized by the presence of an acyclic component structurally resembling part of the ribose moiety in IPA. 
Compounds 3-6 were prepared from 6-chloropurine and 1,2-isopropylidene glycerol or 1,3-isopropylidene 2-hydroxymethyl-1,4-butanediol using a Mitsunobu reaction [7]. Reaction of 6-chloropurine acyclonucleosides with isopentenylamine afforded compounds 3 and 4, whereas with isopentylamine compounds 5 and 6 could be prepared. 
All the synthesized molecules have been tested in biological systems in vitro. The in vitro experiments have been performed on two different human neoplastic cell lines – T24 bladder carcinoma and MCF7 breast cancer - at different concentrations of the compounds. While IPA inhibits the clonogenicity and the proliferation of both T24 and MCF7 cells, the molecules in which the ribose has been modified (compounds 3 and 4) show no effect. A minor modification of IPA side chain (i.e. hydrogenation of the double bond) yielded compound 2 which showed only 50% inhibition of cell growth and clone formation. Acyclonucleosides 5 and 6 derived from isopentylamine were inactive.
Interestingly, neither IPA or compounds 2-6 were capable to inhibit cell migration, a crucial step in invasivity and tumorigenesis. Our results demonstrate that the IPA ribofuranosidic ring is pivotal for its biological activity in vitro. More modified molecules will be synthesized, in order to evaluate structural characteristics required for maintaining the inhibitory action of IPA on cell proliferation and tumour growth.
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